| Chronic heart failure
Entresto vs Furoscix
Side-by-side clinical, coverage, and cost comparison for chronic heart failure.Deep comparison between: Entresto vs Furoscix with Prescriber.AI
AI compares prescribing info and payer-specific access barriers across 1,200+ formularies. Here's a preview of what prescribers are already asking.Safety signalsFuroscix has a higher rate of injection site reactions vs Entresto based on FDA-approved prescribing information
Coverage gaps3 major payers require step therapy for Furoscix but not Entresto, including UnitedHealthcare
Sign up to reveal the full AI analysis
Category
Entresto
Furoscix
At A Glance
Oral
Twice daily
Neprilysin inhibitor / ARB
SC injection
Loop diuretic
Indications
- Chronic heart failure
- Heart failure with reduced ejection fraction
- Edema
- Chronic heart failure
- Chronic Kidney Diseases
- Nephrotic Syndrome
Dosing
Chronic heart failure, Heart failure with reduced ejection fraction Adults: 49/51 mg orally twice daily starting dose; titrate every 2 to 4 weeks to target maintenance dose of 97/103 mg twice daily. Pediatric patients (>=1 year): weight-based dosing titrated every 2 weeks. Reduce starting dose by half for patients not on an ACE inhibitor or ARB, those with severe renal impairment (eGFR <30 mL/min/1.73 m2), or moderate hepatic impairment (Child-Pugh B).
Edema, Chronic heart failure, Chronic Kidney Diseases, Nephrotic Syndrome 30 mg subcutaneously over the first hour followed by 12.5 mg per hour for the subsequent 4 hours (total 80 mg) via On-body Infusor applied to the abdomen; not for chronic use, replace with oral diuretics as soon as practical.
Contraindications
- Hypersensitivity to any component of ENTRESTO
- History of angioedema related to previous ACE inhibitor or ARB therapy
- Concomitant use of ACE inhibitors, or within 36 hours of switching from or to an ACE inhibitor
- Concomitant use of aliskiren in patients with diabetes
- Anuria
- History of hypersensitivity to furosemide, any component of the FUROSCIX formulation, or medical adhesives
Adverse Reactions
Most common (>=5%) Hypotension, hyperkalemia, cough, dizziness, renal failure/acute renal failure
Serious Angioedema, hypotension, impaired renal function, hyperkalemia
Postmarketing Hypersensitivity reactions including rash, pruritus, and anaphylactic reaction
Serious fluid, electrolyte, and metabolic abnormalities, ototoxicity, anaphylactic or anaphylactoid reactions, aplastic anemia, toxic epidermal necrolysis, Stevens-Johnson syndrome, interstitial nephritis, necrotizing angiitis
Other reported pancreatitis, jaundice, nausea, vomiting, tinnitus, hearing loss, vertigo, dizziness, headache, thrombocytopenia, agranulocytosis, leukopenia, rash, erythema multiforme, orthostatic hypotension, injection site erythema and pain, muscle spasm, restlessness
Pharmacology
Neprilysin inhibitor / ARB combination; sacubitril (via active metabolite LBQ657) inhibits neprilysin to increase levels of natriuretic peptides, while valsartan selectively blocks the AT1 receptor and inhibits angiotensin II-dependent aldosterone release, producing combined cardiovascular and renal effects in heart failure.
Furosemide is a loop diuretic that primarily inhibits sodium and chloride reabsorption in the proximal and distal tubules and the loop of Henle, producing high-degree diuresis independent of carbonic anhydrase inhibition or aldosterone.
Enter your patient's insuranceCheck specific coverage details for your patient.
Most Common Insurance
Anthem BCBS
Entresto
- Covered on 5 commercial plans
- PA (10/12) · Step Therapy (0/12) · Qty limit (9/12)
Furoscix
- Covered on 5 commercial plans
- PA (10/12) · Step Therapy (5/12) · Qty limit (9/12)
UnitedHealthcare
Entresto
- Covered on 4 commercial plans
- PA (3/8) · Step Therapy (0/8) · Qty limit (4/8)
Furoscix
- Covered on 4 commercial plans
- PA (5/8) · Step Therapy (4/8) · Qty limit (4/8)
Humana
Entresto
- Covered on 0 commercial plans
- PA (3/3) · Step Therapy (0/3) · Qty limit (3/3)
Furoscix
- Covered on 0 commercial plans
- PA (2/3) · Step Therapy (2/3) · Qty limit (0/3)
Coverage data sourced from MMIT. Updated monthly.
Savings
No savings programs available for Entresto.
No savings programs available for Furoscix.
Let us handle your prior authsJust enter your patient's info and we'll:
- Verify eligibility with the payer.
- Pull the right PA forms directly from the payer.
- Submit, track & send live updates to your dashboard.
Free to start · HIPAA compliant
Next Steps for Your Patient
EntrestoView full Entresto profile
FuroscixView full Furoscix profile
Clinical data sourced from FDA-approved labeling. Coverage data via MMIT. Updated monthly.